All 68 Ga-pentixafor and 18 F-FDG PET/CT scans were performed on a dedicated PET/CT scanner (
Biograph mCT 64; Siemens Medical Solutions). 18 F-FDG PET/CT imaging was performed after a 6-h fasting period to ensure serum glucose levels below 130 mg/dL. Injected activities ranged from 108 to 178 MBq (mean, 143 6 26 MBq) for 68 Ga-pentixafor and from 235 to 363 MBq (mean, 299 6 18 MBq) for 18 F-FDG.
Low-dose CT scans for attenuation correction were acquired (35 mAs, 120 keV, a 512 • 512 matrix, 5-mm slice thickness, increment of 30 mm/s, rotation time of 0.5 s, and pitch index of 0.8). Whole-body (top of the skull to knees) scans were performed 1 h after administration of the radiopharmaceutical. All PET images were reconstructed using standard parameters (
HD-PET [Siemens]; 3 iterations, 24 subsets, 2-mm gaussian filtering, 5-mm axial resolution, 4 • 4 mm 2 in-plane resolution) with corrections for attenuation (CT-based), dead time, random events, and scatter. The PET scanner is periodically checked for calibration accuracy as part of quality control according to published guidelines (34) .
Kircher M., Tran-Gia J., Kemmer L., Zhang X., Schirbel A., Werner R.A., Buck A.K., Wester H.J., Hacker M., Lapa C, & Li X. (2020). Imaging Inflammation in Atherosclerosis with CXCR4-Directed 68Ga-Pentixafor PET/CT: Correlation with 18F-FDG PET/CT. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 61(5).